GlassScriptPhysician profile
Naya Mckinnon
NPI 1841229929
$662.70
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $34.06 · 2021: $21.85 · 2022: $61.41 · 2023: $143 · 2024: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $355.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $106.74 | 2019-2024 | |
| Janssen Biotech, INC. | $59.04 | 2023-2024 | Tremfya |
| Ptc Therapeutics, INC. | $57.29 | 2019-2023 | Emflaza |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $55.33 | 2019-2020 | |
| Sarepta Therapeutics, INC. | $54.63 | 2019-2023 | Elevidys |
| Tanabe Pharma America, INC. | $43.50 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $42.88 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.70 | 2023-2024 | Cyltezo |
| Biogen, INC. | $24.22 | 2019 | |
| Grifols USA, LLC | $22.27 | 2024 | Gamunex-C |
| Amylyx Pharmaceuticals, INC. | $22.08 | 2023 | Relyvrio |
| Aurinia Pharma U.S., INC. | $21.85 | 2021 | |
| Sandoz INC. | $20.90 | 2024 | Hyrimoz |
| Genentech USA, INC. | $20.83 | 2019 | |
| Kyowa Kirin, INC. | $20.52 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $20.37 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.21 | 2024 | |
| Genzyme Corporation | $15.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naya Mckinnon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.